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Repeated intravenous doses of all-trans-retinoyl β-D-glucuronide is not
effective in the treatment of bacterial bronchopneumonia in lambs but is
devoid of gross and acute toxicity
Abstract
Background
All-trans-retinoyl β-D-glucuronide, a water-soluble glucuronic acid conjugate of all-transretinoic acid, has
demonstrated high biological activity and low toxicity in most in vitro and in vivo models. Since the reparative
effects of retinoids on epithelium are well-known, our aim was to study the effect(s) of intravenously-
administered all-trans-retinoyl β-D-glucuronide in lambs with chronic bacterial bronchopneumonia.
Material/Methods
Two groups of lambs were inoculated intrabronchially with either pyrogen-free saline or Mannheimia
haemolytica. Thirty-three days later, lambs were injected four times at five-day intervals with 2 mL of 116 mM
all-trans-retinoyl β-D-glucuronide (6.0–9.3 µmol/kg or 2.86–4.42 mg/kg animal body weight) in dimethyl
sulfoxide, or dimethyl sulfoxide alone. Animal behavior and signs of clinical illness were logged daily. Lung
and liver samples were assessed for histopathology, while serum and liver samples were extracted for retinoids
and analyzed by reversed-phase gradient high-performance liquid chromatography.
Results
Repeated injections of highly concentrated all-trans-retinoyl β-D-glucuronide did not cause changes in
appetite, activity or other behaviors nor did it cause histologic lesions in liver and lung. However, it had no
effect on resolution of lung lesions resultant of chronic Mannheimia haemolytica bronchopneumonia.
Conclusion
Repeated intravenous administration of high amounts of all-trans-retinoyl β-D-glucuronide to lambs did not
elicit signs of gross or microscopic toxicity. However, administering all-transretinoyl β-D-glucuronide too late
in the progression of bacterial pneumonia is thought to be the main reason for its lack of effect in this model. A
retinoid lactone derivative was detected in sheep serum and liver several days after treatment.
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Summary
Background: All-trans-retinoyl β-D-glucuronide, a water-soluble glucuronic acid conjugate of all-trans-
retinoic acid, has demonstrated high biological activity and low toxicity in most in vitro and in
vivo models. Since the reparative effects of retinoids on epithelium are well-known, our aim
was to study the effect(s) of intravenously-administered all-trans-retinoyl β-D-glucuronide in
lambs with chronic bacterial bronchopneumonia.
Material/Methods: Two groups of lambs were inoculated intrabronchially with either pyrogen-free saline or
Mannheimia haemolytica. Thirty-three days later, lambs were injected four times at five-day
intervals with 2 mL of 116 mM all-trans-retinoyl β-D-glucuronide (6.0–9.3 µmol/kg or
2.86–4.42 mg/kg animal body weight) in dimethyl sulfoxide, or dimethyl sulfoxide alone.
Animal behavior and signs of clinical illness were logged daily. Lung and liver samples were
assessed for histopathology, while serum and liver samples were extracted for retinoids and
analyzed by reversed-phase gradient high-performance liquid chromatography.
Results: Repeated injections of highly concentrated all-trans-retinoyl β-D-glucuronide did not cause
changes in appetite, activity or other behaviors nor did it cause histologic lesions in liver and
lung. However, it had no effect on resolution of lung lesions resultant of chronic Mannheimia
haemolytica bronchopneumonia.
Conclusion: Repeated intravenous administration of high amounts of all-trans-retinoyl β-D-glucuronide to
lambs did not elicit signs of gross or microscopic toxicity. However, administering all-trans-
retinoyl β-D-glucuronide too late in the progression of bacterial pneumonia is thought to be
the main reason for its lack of effect in this model. A retinoid lactone derivative was detected
in sheep serum and liver several days after treatment.
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BACKGROUND
Vitamin A specifically refers to vitamin A alcohol, retinol
(ROH) and its isomers, but also represents a larger group
of compounds, known collectively as retinoids, which
have been most recently defined as compounds struc-
turally similar to retinol, or that elicit specific biological
responses by binding to and activating a specific receptor
or set of receptors [1,2]. All-trans-retinoic acid (RA) medi-
ates its biologic effect by binding to nuclear retinoic acid
receptors (RAR-α, β, γ) and/or retinoid X receptors
(RXR-α, β, γ) [3]. An in vitro study performed on rabbit
tracheal epithelial cells showed that receptor agonists act
as metaplastic inhibitors with RARα and RARβ, and
RXRs to a lesser extent, while RARα induces apoptosis in
proliferating epithelial cells in the S-phase [3]. To
increase the transcription of their target genes, these
nuclear receptors bind specific DNA sequences (retinoic
acid response element; [4,5]). Because retinoids decrease
growth of epithelial cells and fibroblasts, enhance differ-
entiation, and reduce collagen synthesis [6], they have a
profound direct effect on lung cells and are potentially
therapeutic for pulmonary diseases. In the lung,
retinoids and retinoic acid receptors are present in high
levels during fetal maturation, but decrease rapidly after
birth along with retinoic acid receptors. During cell
injury and in immature cells, retinoid receptors are again
upregulated. In neonatal rats, RA enhances formation of
alveoli, increases the number of alveoli, and abrogates
elastase-induced pulmonary emphysema [7,8]. Retinoids
enhance development of the fetal lung; RA also appears
to have an effect on both the pulmonary mesenchyma
and epithelia [9]. RA accelerates lung septation and
branching resulting in increased formation of alveoli
[9,10], and lung growth is enhanced by RA in animals
after experimental pneumonectomy [11]. Vitamin A defi-
ciency results in reduced lung elastin, and reduced sur-
factant biosynthesis and ornithine decarboxylase activity
by respiratory type II cells [9,12]. And rats sustained on a
vitamin A-deficient diet exhibit inflammation of the lungs
and emphysema (as evidenced by increased size of air
spaces distal to the terminal bronchiole with thinning and
partial or total destruction of septal wall) indicating that a
lack of vitamin A results in emphysemic lungs [12].
Additionally, β-carotene (provitamin A) supplemented
diet decreases pneumotoxin monocrotaline (MCT)
induced inflammation in rat lung [13]. Currently, the
effect of retinoids on lung repair following bacterial infec-
tion has not been determined.
Although RA has already shown to be effective in treating
acute promyelocytic leukemia (APL) and cystic acne in
humans, the use of RA can result in adverse side effects
[14]. A naturally-occurring glucuronic acid conjugate of
RA, all-trans-retinoyl β-D-glucuronide (RAG) has poten-
tial advantages over RA and other retinoids in solubility
and toxicity, and for the first time demonstrated its
potent biological activity and lack of toxicity in the differ-
entiation of HL-60 cells into normal neutrophils [15,16].
Though RAG was subsequently shown to be transported
to the nucleus (in HL-60 cells) [17], it is not known with
certainty whether RAG is biologically active per se or by
virtue of its hydrolysis to small amounts of RA. RA can be
detected in small amount after administration of RAG by
intraperitoneal (IP), intramuscular (IM) or intravenous
(IV) injection [18–21]. Therefore, it can be expected that
RAG may serve as a non-toxic pro-RA. Unlike most
retinoids, including RA, which are lipid soluble, RAG is
water-soluble [22]. This property makes it ideal for IV or
aerosol application. Additionally, RAG is non-toxic when
either absorbed through the skin after topical applica-
tions, or by the digestive tract following oral administra-
tions, while most retinoids are toxic at high doses.
Further, RAG seems not to induce its own metabolism
e.g. during two-month daily subcutaneous injections of
RAG into rats, peak plasma levels remain elevated. RA,
on the contrary, rapidly induces its own metabolism [23],
and therefore greatly limits its own activity. Even though
both RA and RAG achieve peak plasma concentrations
within 1–2 hours after subcutaneous injections of RAG
into rats, RA (now a RAG metabolite) is cleared rapidly
from the plasma whereas RAG is eliminated much more
slowly. RAG has also been reported to be roughly sixteen
times less potent in inducing teratogenicity than RA [24].
When RAG was administered orally to pregnant
Sprague-Dawley rats (110–380 µmol/kg animal body
weight) on day 8.5 of gestation, it did not produce terato-
genic effects, while RA did. This is due to a much slower
rate of RAG absorption by the GI, its slower rate of
hydrolysis to RA, and its limited passage into the embryo.
However, Nau et al. have shown that smaller doses of
RAG (20 µmol/kg animal body weight) administered sub-
cutaneously to pregnant NMRI mice on day 11 of gesta-
tion, resulted in high incidence of teratogenicity. The dis-
crepancy between these results might be explained by a
higher rate of RAG conversion to the teratogenic RA in
NMRI mice as compared to Sprague-Dawley rats or even
other strains of mice, i.e. ICR mice. Lastly, RAG is similar
in efficacy to RA in treatment of acne in humans, but
without the same side effects [25].
The purpose of this study was to: 1) develop a formula-
tion in which high concentrations of RAG can be inject-
ed IV, and 2) determine if repeated doses of RAG can
be tolerated by sheep, and 3) determine if such treat-
ments are beneficial in repair of lung lesions resultant of
chronic bacterial bronchopneumonia.
MATERIAL AND METHODS
Clearance to use animals
Animal use was approved by Iowa State University’s
Animal Care and Use Committee.
Synthesis of all-trans-retinoyl β-D-glucuronide
RAG used in this study was chemically synthesized in
high yields with the use of the phase-transfer catalyst,
tetra-butylammonium hydroxide according to previous-
ly published methods [26].
IV injection considerations
IV injection into the external jugular vein was chosen as
the method of delivery because: 1) it is convenient for
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large animals, 2) most of the blood carrying RAG in the
external jugular vein goes directly to the heart and then
the lung, thus allowing recently injected RAG to rapidly
enter the pulmonary circulation and avoid the systemic
circulation, 3) the amount of RAG injected intravenous-
ly and entering the circulation can be readily quantified
(in comparison to the difficulties expected when trying
to quantify amounts of RAG delivered by aerosolic
application; losses of RAG in the nasal cavity, by animal
sneezing or ingestion, external losses etc.). The initial
concentration we desired to attain in sheep plasma was
100 µM, a dose based on studies in rats [see again refer-
ence 21]. Because we desired IV injections, we sought to
concentrate RAG into the smallest, least invasive volume
of vehicle; a volume which would be reasonable to inject
into both young and adult sheep and other animals
species. Although significantly water-soluble, RAG, like
other retinoids, is highly soluble in DMSO, and after
attempting several RAG formulations in aqueous buffers
with and without DMSO, we decided to use 2 mL of
DMSO as the dosage vehicle.
Formulation of RAG for IV injections
A stock solution of 116 mM RAG in 79 mL of 99.9%
DMSO (Sigma, St. Louis, MO, Cat. No. D-8418) was
carefully prepared under yellow light using freshly-syn-
thesized, RAG. The concentration of the RAG stock
solution was checked by measuring several serial
methanolic dilutions of it in a spectrophotometer. The
RAG/DMSO injection solution was stored at 4°C in an
amber glass bottle (sealed under argon), and for injec-
tions, only the amount needed for each of the 4 days
pre-designated for RAG/DMSO administration was
taken from the bottle (by pouring the desired volume
into an aluminum foil-wrapped 50 mL conical cen-
trifuge tube).
Experimental design
Weaned lambs (n = 3 or 4/group) (3 months of age,
either sex) were separated into four groups (Table 1),
based on the type of intrabronchial inoculations and IV
injections they received. Immediately prior to intra-
bronchial injections, sheep were sedated with xylazine
(0.1 mg/kg, IV), then they received either 5 mL pyro-
gen-free saline (PFS; Groups 1 and 2) or Mannheimia
haemolytica in PFS (5 mL 1×109 cfu/mL; Groups 3 and 4).
The PFS and M. haemolytica were deposited in the right
tracheal bronchus of each animal with a fiberoptic bron-
choscope as described previously [27,28]. At days 33, 38,
42 and 47 after the intrabronchial inoculations, sheep
received IV injections of 2 mL of either DMSO alone
(Groups 1 and 3) or DMSO containing 116 mM RAG
(Groups 2 and 4) in the external jugular vein. Serum,
respiratory tissues and liver were collected 50 days after
the intrabronchial inoculations. RAG/DMSO-treated
lambs received a calculated initial average plasma con-
centration of 147 µM RAG; the highest calculated initial
plasma concentration of RAG in any RAG/DMSO-treat-
ed lamb was 193 µM.
Injections
Each lamb received a constant 2 mL of 116 mM RAG in
DMSO by IV injection regardless of body weight during
the intrajugular administrations (and the RAG/DMSO
was mixed with each sheep’s blood within the injection
syringe prior to each injection to avoid ‘clustering’ of
RAG in the bloodstream). Among lambs that received
the 2 mL injections of 116 mM RAG/DMSO, animal
body weights ranged from 25 kg to 38.64 kg, which
accounted for calculated initial plasma concentrations of
RAG ranging from 125 µM to 193 µM. Sheep plasma
volume (in liters) was calculated to be 0.048 fraction of
each animal’s body weight; 8% of the body weight was
the calculated blood volume and 60% of the blood vol-
ume was the calculated plasma volume in each case.
Animal behavioral observations
Animals were monitored twice daily for respiratory dis-
tress (increased respiration, coughing and dyspnea),
and general behavior (eating, drinking, sleeping, and
interactions with pen-mates). Any changes were logged
in a record book attached to the door of each room.
Clinical symptoms (slight fever, increased respiration
and mild coughing) were first detected during days 1–3
post inoculation with M. haemolytica.
Preparation and storage of serum and liver samples
10 mL of blood was collected from the jugular vein of
each animal prior to euthanasia, the blood was allowed
to clot and the serum was clarified by spinning at 200 x
g in a tabletop centrifuge for 15 minutes at room tem-
perature after which the (top) serum layer (2–4 mL) was
removed and stored in cryo-vials at –80°C until needed
for retinoid extraction. Prior to being extracted for
retinoids, liver samples were collected on the day of
necropsy, transferred immediately to cryo-vials and
stored at –80°C until needed.
Preparation of slides for microscopic histopathology
At necropsy, animals were euthanized by IV injection
with an overdose of sodium pentobarbital immediately
prior to tissue collection. Lung tissues were collected
from the central area of the inoculation site of each M.
haemolytica-treated animal and corresponding sections
were taken from saline-treated control animals. Tissues
were fixed in 10% neutral-buffered formalin for 24–48
hours. Following fixation, tissues were processed for 48
1
2
3
4
3
4
3
4
* PFS denotes pyrogen-free saline; ** 2 mL of 116 mM RAG dissolved in 99.9%
DMSO; *** Values are expressed as mean±SD
PFS*
PFS
M. haemolytica
M. haemolytica
DMSO
DMSO/RAG**
DMSO
DMSO/RAG
0
146.0±31.7***
0
147.5±13.2
Group
no.
No.
of sheep
Intrabronchial
inoculation
Intravenous
inoculation
Initial [RAG]
in plasma (mM)
Table 1. Experimental design for injections of RAG into sheep with
and without chronic bacterial bronchopneumonia.
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hours in an automated tissue processor and embedded
in paraffin. Embedded tissues were then sectioned (3–5 µm)
by microtome (according to standard histopathology
procedures) and affixed to silanated glass specimen
slides. Sections were then stained with hematoxylin and
eosin (H&E) and evaluated for histological changes by
light microscopy.
Extraction of retinoids from serum
Retinoids from serum were extracted according to pub-
lished procedure [29,30]. In brief, serum was extracted
with ethyl acetate and hexane in presence of ethanol
containing BHT, and acetic acid. Retinyl acetate was
used as the internal standard. The extract was evaporat-
ed to dryness under argon in a water bath at 39°C. The
final dried residue was dissolved in 100 µL of (2:1) 2-
propanol/dichloromethane and 90 µL of the resulting
solution was subjected to reversed-phase gradient
HPLC analysis.
Extraction of retinoids from liver
The procedure for extraction of retinoids from liver was
the same as published [30]. In brief, 0.5 g of liver was
extracted with a mixture of 2-propanol/dichlorome-
thane (×3) in the presence of retinyl acetate and BHT
(internal standard and antioxidant, respectively). The
extract was then evaporated to dryness under argon,
and then dissolved in 500 µL of (1:1) 2-propanol/dichlo-
romethane and any remaining debris at this point was
centrifuged out. The clarified solution was transferred
to a clean tube and 90 µL was subjected to reversed-
phase gradient HPLC analysis.
Saponification of retinoid extracts
A dried retinoid extract (of serum or liver, etc.) was sa-
ponified by reflux with methanolic sodium hydroxide in
the presence of a trace amount of BHT. The retinoids
were extracted, after acidification with dilute acetic acid,
with a mixture of ethyl acetate and hexane. The organic
phase was evaporated to dryness at 39°C under argon.
The final residue was dissolved in 100 µL of (2:1) 2-
propanol/dichloromethane (for extracts from liquid
samples, i.e. serum, urine or bile) or 500 µL of (2:1) 2-
propanol/dichloromethane (for extracts from liver), and
90 µL of each was subjected to reversed-phase gradient
HPLC analysis.
β-Glucuronidase treatment of retinoid extracts
Incubation of retinoid extracts with β-glucuronidase
enzyme was carried out according to published proce-
dure [31]. Final extract residues were dissolved in 100 µL
of (2:1) 2-propanol/dichloromethane (for extracts from
liquid samples, i.e. serum, urine or bile) or in 500 µL of
(2:1) 2-propanol/dichloromethane (for extracts from
liver), and 90 µL of each was subjected to reversed-
phase gradient HPLC analysis.
Reversed-phase gradient HPLC
For analysis of reference compounds, serum and liver
retinoids, a previously published reverse-phase gradient
HPLC procedure was used (see [29]).
RESULTS
Animal behavioral studies
All lambs inoculated with M. haemolytica developed res-
piratory changes (increased respiratory rate, some
coughing) typical of Mannheimia haemolytica-induced
pneumonia for up to 7 days after infection. Lambs
receiving pyrogen-free saline lacked any changes and
appeared normal. After 7–14 days, lambs begin to
develop chronic bronchopneumonia in this model [32],
and lack clinical disease (changes in respiration rate,
body temperature, coughing or wheezing etc.). At the
time of RAG/DMSO or DMSO administration in this
study, lambs lacked signs of clinical disease and behav-
ioral abnormalities. There was no increase or decrease
in water or food consumption or alterations in sleep or
other behavior. On one occasion, animals receiving
RAG (both infected and uninfected) seemed to be ‘more
lively or energetic’ than lambs receiving just DMSO.
Gross Pathology
There were no gross lesions in the abdomen and thorax
of the control animals. Animals inoculated with M.
haemolytica had focal areas of consolidation at the site of
bacterial deposition. No other lesions were seen in any
animal.
Histopathology
For histopathology, sections of lung from all bacteria-
inoculated animals were found to contain lesions typical
of chronic M. haemolytica bronchopneumonia. These
lesions were characterized by marked multifocal thick-
ening of alveolar walls by fibrous connective tissue and
type II cell hypertrophy and hyperplasia as well as mod-
erate to marked bronchiolar epithelial hyperplasia.
Lungs of animals lacking M. haemolytica infection had
only minimal to mild peribronchiolar and peribronchial
infiltrates of lymphocytes and plasma cells. Animals
receiving either RAG/DMSO or DMSO alone lacked
additional microscopic lesions in respiratory tract
including trachea and lung. There were also no micro-
scopic lesions in the liver of any animal.
Reversed-phase gradient HPLC analysis
Analysis of retinoid standards yielded the typical
retinoid elution profile characteristic of this HPLC
method (Figure 1). Analysis of retinoid extracts from
serum and liver showed that retinol and retinyl esters
were the major retinoids in serum and liver, respective-
ly (Figures 2 and 3). Neither RAG nor RA were detected
in serum or liver samples collected 4 days after the last
RAG injection. However, serum and liver extracts from
RAG/DMSO-treated animals revealed a metabolite of
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all-trans-retinoyl β-D-glucuronide which was less polar
than retinoyl β-D-glucuronide, retinoic acid, retinol and
retinyl acetate (Figures 1–3). The metabolite showed an
absorption spectrum similar to that of retinoyl β-D-glu-
curonide at 358 nm (tr = 29.7 minutes). Serum and
liver extracts from control (DMSO-treated) animals did
not show this peak at 29.7 minutes. When serum or
liver extracts of RAG/DMSO-treated lambs were incu-
bated with β-glucuronidase or saponified, the metabo-
lite peak at 29.7 minutes disappeared with the appear-
ance of a peak at 16.8 minutes, which is the retention
time of RA (Figure 4). The absorption spectrum of this
peak was 338 nm indicating that it was RA. Because the
metabolite of RAG produced RA on treatment with β-
glucuronidase, the metabolite must contain a glucuronic
acid moiety. Because RAG can lactonize easily [23,34],
and is much less polar than RAG, the metabolite has
been tentatively identified as retinoyl β-glucuronolac-
tone (RAGL). Retinoid extraction efficiencies from
sheep serum and sheep liver were calculated to be
90.57±15% and 75.82±18%, respectively.
DISCUSSION
Attempts to prepare highly concentrated solutions of
RAG in 0.9% saline or PBS were not successful,
although up to ~20 mM could be prepared in HPLC-
grade water. Our original idea was to design a 5-mL
parenteral aqueous formulation that delivered enough
Figure 1. Reversed-phase gradient HPLC chromatogram of retinoid
standards obtained at 329 nm. Peak identification: 
1: all-trans-retinoyl β-D-glucuronide; 2: all-trans-retinoic
acid; 3: all-trans-retinol; 4: all-trans-retinyl acetate; 
5: all-trans-retinoyl β-D-glucuronolactone; 6: all-trans-retinyl
palmitate.
Figure 2. Reversed-phase gradient HPLC chromatogram of serum
retinoid extract from a RAG/DMSO-treated lamb showing the
accompanying spectrum index plot. Peak identification: 
1: 13-cis-retinol; 2: all-trans-retinol; 3: retinyl acetate;
4: retinoyl β-D-glucuronolactone. (Sample was collected at
necropsy 3 days after the final RAG/DMSO injection).
Figure 3. Reversed-phase gradient HPLC chromatogram of liver
retinoid extract from a RAG/DMSO-treated lamb (before
treatment with β-glucuronidase enzyme) showing the
accompanying spectrum index plot. Peak identification: 
1: retinol; 2: retinyl acetate; 3: retinoyl β-D-glucuronolactone;
4: retinyl palmitate. The common array of retinyl esters are
observed between 31 and 45 minutes. (Sample was collect-
ed at necropsy 3 days after the final RAG/DMSO injection).
Figure 4. Reversed-phase gradient HPLC chromatogram of liver
retinoid extract from a RAG/DMSO-treated lamb (after treat-
ment with β-glucuronidase enzyme) showing the accompa-
nying spectrum index plot. Peak identification: 1: retinoic
acid; 2: 9-cis retinol; 3: all-trans-retinol; 4: retinyl palmitate.
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RAG to 30–40 kg lambs to establish initial plasma con-
centrations of at least 100 µM, a concentration similar to
that used for the treatment of elastase-induced lung
injury in rats (and more directly comparable with what
Ho et al. did in rats by administering 0.83, 1.67 and 2.5
mL injections of a 2.1 mM RAG/0.9% saline-20% (w/v) 2-
hydroxypropyl β-cyclodextrin (HPβCD) formulation to
establish 5, 10 and 15 µmol/kg animal body weight,
respectively (see again [21]). However, we found that we
could not concentrate RAG enough in any aqueous
medium alone to form the desired dose. Combinations
of DMSO + 0.9% saline and DMSO + PBS pH 7.4 were
attempted, but both saline and PBS severely limited
RAG’s solubility in DMSO. Since all retinoids, including
RAG were known to be highly soluble in pure DMSO,
the final vehicle chosen for this study was 99.9% DMSO
lacking saline or PBS altogether. Although IV delivery
of repeated high doses of RAG in DMSO has not been
previously attempted, repeated IV administrations of
RAG in 0.9% saline containing 20% (w/v) HPβCD to
Sprague-Dawley rats has been performed, and the first
detailed account of RAG pharmacokinetics described
[see again ref. 21]. In our study, the average calculated
initial plasma concentration of RAG established in lambs
receiving 2 mL of 116 mM RAG in DMSO was 147 µM,
which is nearly 7,300 times its normal average circulat-
ing level (19.95±9.45 nM) in mammalian serum (5–17
nM in human serum). After each injection (averaging
7.6 µmol RAG/kg sheep body weight), RAG could have
been in part excreted into the bile and/or converted to
RA, most likely by the activity of β-glucuronidase. This
enzyme has been found in bovine liver [35], milk [36],
seminal plasma [37]; in mono- and granulocytic blood
cells from different domestic animal species including
sheep [38]; in rabbits [39]; and rats. In the study with
rats, where RAG was administered orally to vitamin A-
deficient animals, RAG was rapidly hydrolyzed to RA,
compared to vitamin A-sufficient rats where RAG and
traces of RA appear only randomly in the plasma [40].
In target tissues, RA was found in higher amount than
RAG in vitamin A-deficient rats, while RAG was much
more abundant in vitamin A-sufficient rats. This change
in RA/RAG ratio demonstrates the need for RA in target
tissues. On the other hand, when no more RA is need-
ed, it is sequestered by proteins and/or converted back
into a physiologically less active form, RAG [41]. Both α
and β-glucuronide conjugates of RA (the retinoyl glu-
curonides) and α and β-glucuronide conjugates of ROH
(the retinyl glucuronides) were first recognized and
identified as polar retinoid metabolites in the bile [42],
small intestine [43], and liver [44] of the rat (in the pres-
ence of UDP-glucuronic acid, RA and ROH are convert-
ed to their respective α and β-glucuronides by UDP-glu-
curonosyltransferase enzyme (see [18]). Without being
hydrolyzed to RA, these conjugates could serve as a
source of RA.
Since we wished to observe the effect(s) of RAG/DMSO
on chronic lung lesions, we administered RAG/DMSO
late in the progression of experimentally-introduced M.
haemolytica pneumonia. Mannheimia haemolytica is a com-
mon bacterial pathogen of the respiratory sheep and
cattle throughout the world that can cause severe pneu-
monia and sometimes death. If animals survive initial
infection, chronic lung lesions persist. These lesions
impair gaseous exchange and can be a nidus for re-
infections or secondary infections. M. haemolytica colo-
nizes the tonsil and nasal cavity and at times of stress
(shipping, overcrowding) or viral infection, proliferation
of M. haemolytica increases. Vaccines are not fully protec-
tive.
For treatments, we administered 2 mL injections of 116
mM RAG/DMSO four times at 5-day intervals, with the
first one being given 33 days post intrabronchial inocu-
lations of either Mannheimia haemolytica or saline, and
the last one being given 3 days before animal sacrifice.
Clinical consequences of acute hypervitaminosis A,
which include vomiting, stupor, papilledema [45], were
not observed in RAG/DMSO-treated lambs. Animal
behavior remained normal and constant throughout
the studied period, and there were no thoracic or
abdominal gross lesions. Histopathology of trachea,
lung, and liver showed no significant differences
between RAG/DMSO-treated and DMSO-treated
lambs, illustrating the non-toxic feature of intravenous-
ly introduced RAG (and DMSO for that matter).
Lesions of lung resultant of M. haemolytica-induced
bronchopneumonia (characterized by microscopic
inspection of hematoxylin and eosin-stained lung sec-
tions on glass slides) were identified as areas with pro-
nounced multifocal alveolar-wall thickening (from
build-up of fibrous connective tissue), and type II cell
hypertrophy and hyperplasia, and moderate to severe
bronchiolar epithelial cell hyperplasia. Lungs of ani-
mals lacking infection, whether treated with
RAG/DMSO or just DMSO, had only minimal to mild
peribronchiolar and peribronchial infiltrates of lym-
phocytes and plasma cells. Although this study suggests
that RAG is not toxic to sheep when given IV at high
doses, additional studies are required to assess the
effects of RAG weeks and months after administration.
Our goal to determine whether or not RAG/DMSO
administration altered chronic lesions of M. haemolytica-
induced bronchopneumonia was clear in that the treat-
ment appeared to have no effect. The inability of RAG
to structurally alter chronic lung lesions may have been
due to several reasons. First, the administration of RAG
(33 days after the pneumonia was initiated) when the
chronic lesions were already well established may have
been too late to affect lung epithelial cell differentiation
and proliferation. In future studies, we will determine if
RAG can enhance repair of lung lesions when injected
intravenously during the initial (acute) stages of bacteri-
al pneumonia. Second, although the timing of RAG
administration may have been appropriate, the lung
may require more time after administration for lesions
to be altered. In this study, lung tissue was collected 17
days after the first RAG inoculation. In studies of RAG
in the treatment of acne in skin, months can be required
before a noticeable change in lesions becomes evident or
measurable.
HPLC analyses of sheep serum and liver extracts from
the present study showed that RAG administered by IV
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injection was metabolized to a compound that was very
similar to RAG. The UV-visable absorption spectrum of
both RAG and the new metabolite was the same. Both
produced RA on treatment with β-glucuronidase point-
ing toward the presence of a glucuronic acid moiety in
the metabolite (Figures 3 and 4). However, the reten-
tion time of the compound during HPLC analysis was
different from RAG. The longer retention time of the
metabolite in question indicated that it might be a lac-
tone derivative of RAG (Figures 1–3). This has been
concluded for several reasons: during column chro-
matography of pure RAG (as evidenced by a single peak
during HPLC) on silica gel, a small fraction of some-
thing other than RAG always eluted with a solvent mix-
ture of methanol and dichloromethane much earlier
than RAG (unpublished observations in this laboratory).
The uv-visable spectra of RAG and the early-eluting
fraction were found to be similar. During HPLC, the
retention time of the early fraction was found to be
much longer (29.7 minutes) than RAG (15.2 minutes),
RA (16.8 minutes) retinol (22.4 minutes) and retinyl
acetate (27.3 minutes). This change in chromatographic
behavior of RAG pointed towards chemical modification
of RAG. Since γ-lactones form spontaneously and enzy-
matically [46], and because glucuronic acid easily under-
goes lactonization to glucurono 3,6-lactone, it is possible
that the glucuronic acid moiety in RAG underwent lac-
tonization. The formation and identification of retinoyl
β-glucurono-γ-lactone during an isolation procedure
was reported following incubation of RAG with an
anion-exchange resin in the presence of methanol. The
retention time of the metabolite of RAG found presently
in sheep serum (and in rat serum: unpublished results.
David Romans, Arun Barua and James A. Olson) is
same as the compound formed from RAG during col-
umn chromatography. It was, however, not clear
whether this lactone was formed from RAG during the
isolation procedure or prior to it. Based on these obser-
vations, the metabolite isolated as a major product in rat
serum following IP injection of RAG, and noted as a sig-
nificant RAG metabolite in sheep serum in the present
study, has tentatively been identified as retinoyl β-glu-
curono-γ-lactone (RAGL); the 5-membered (inner ester)
ring formed by the glucuronic acid moiety of γ-lactone is
known to be a more common arrangement than the 6-
membered (inner ester) ring found in δ-lactone [47].
HPLC analyses of serum and liver extracts performed 3
to 5 days after the fourth and last RAG administration
showed that RAG and RA had already returned to nor-
mal/undetectable levels, while the (RAGL) peak at 29.7
minutes was present only in extracted serum and livers
from RAG/DMSO-treated lambs. It is possible that the
lingering glucuronolactone was formed as a byproduct
in serum resulting from RAG overload. And, whether or
not the seemingly slow clearance of the retinoyl β-glu-
curonolactone from blood is due to a lack of affinity for
cellular RA binding protein (CRABP) or nuclear recep-
tors of RA (RARs), like RAG [48], or due to it merely
being an atypical, lingering byproduct to be expected in
the aftermath of such mega-dosing, is unknown.
Regardless, the retinoyl β-glucuronolactone (RAGL) is
not being cleared or metabolized as quickly as one
might expect with RA (within 6 to 8 hours) or RAG (by
24 hours) in rats, mice or humans. However, inter-
species differences with respect to retinoid clearance or
metabolism are important to note, i.e. NMRI mice and
Wistar rats were shown to be very different in that
serum levels of orally administered 9-cis-retinoyl β-glu-
curonide were elevated in the mice far and above that
seen in the rats 1 hour after each had received an
equimolar dose (210 µmol/kg animal body weight) of
the retinoid. Further, although RA exposure has been
shown to promote surfactant production in fetal rats
and to promote alveolization in neonatal rats, RA given
to late gestation preterm sheep (10–20 mg/kg or
33.3–66.6 µmol/kg animal body weight) did not appear
to accelerate structural or functional maturation of the
fetal sheep lung [12].
Besides their potential use in the therapy of respiratory
diseases, retinoids are already well used in dermatology
and oncology. Topically applied RAG is very effective in
treating moderate to moderately severe acne in
humans. Furthermore, RA plays a central role in the
present therapy for acute promyelocytic leukemia (APL)
[49], and is also beneficial in the treatment of neuroblas-
toma [50], head-and-neck-tumors [51], multiple myelo-
ma, lung or breast cancer [52]. But, since RA brings
about its own metabolism by inducing CRABPs and
Cytochrome P-450 (CYP 450) enzymes after repeated
dosing, thereby limiting its own clinical value, and since
RAG lacks binding affinity for CRABP (and therefore
cannot be transported to the endoplasmic reticulum to
be oxidized by the CYP 450 enzyme system, like RA),
RAG appears to be the retinoid most likely to succeed in
cases where RA has already been demonstrated to
become less effective with prolonged administration.
Since nearly twenty five percent of RA-treated APL
patients develop toxic ‘retinoic acid syndrome’, which
can be fatal [53,54], an alternative to RA in such treat-
ments is very much needed. In clinical situations, where
mode of retinoid delivery is a concern, and since the use
of DMSO as a vehicle for drug delivery to humans is not
approved by the FDA, other solvents (in addition to
aqueous formulations using HPβCD) are currently
being sought out, such as Soluphor P (2-pyrrolidone),
Lutrol E (PEG) and Solutol HS 15 (PEG hydroxys-
tearate), which are approved for human use [55].
CONCLUSIONS
Highly concentrated, repeated doses of RAG can be given
IV to lambs/sheep without overt alterations in behavior,
gross lesions, or microscopic lesions in liver and lung.
Several days after RAG injections, a lactone derivative
develops in the serum and liver of lambs. Multiple high
doses of RAG do not resolve established lesions resultant
of chronic bacterial bronchopneumonia.
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